ArticleEndocrine pathology2024
Clinicopathologic and Molecular Analysis of 15 Pediatric and Young Adult Patients with High-Grade Non-anaplastic Thyroid Carcinoma.
Article in Endocrine pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2025Guideline
- Clinicopathologic and Molecular Features of Poorly Differentiated Thyroid Carcinomas in Adults ≤ 45 Years of Age.Endocrine pathology · 2026Article
- Ultrasound features of thyroid follicular adenoma and follicular carcinoma: A narrative review.The Journal of international medical research · 2026Review
- DICER1-Related Pediatric Thyroid Neoplasm with Follicular and Morular Growth: A Tumor that Did Not Read the Textbook.Endocrine pathology · 2025Article
- Identification of Oncogenic Alterations in 124 Cases of Pediatric Papillary Thyroid Carcinoma: BEND7::ALK, DLG5::RET, and CCDC30::ROS1 Fusions Induce MAPK Pathway Activation.Endocrine pathology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade follicular cell-derived non-anaplastic thyroid carcinomas are uncommon and typically diagnosed in the sixth to seventh decade of life. These tumors are rare in the pediatric (≤ 18 years old) and young adult (19-21 years old) populations. The molecular landscape of pediatric and young adult thyroid neoplasia has been suggested to be enriched in DICER1 gene alterations. Our intent was to evaluate pediatric and young adult high-grade follicular cell-derived non-anaplastic thyroid carcinomas for driver mutations. Thyroid carcinomas involving individuals under the age of 21 years were retrieved from our institutional archives. The patient population included 13 females and 2 males aged 9-20 years. Six patients were aged 9-16 years and nine patients were aged 19-20 years. The carcinomas were classified as poorly differentiated thyroid carcinoma (PDTC) (n = 6) and differentiated high-grade thyroid carcinoma (DHGTC) (n = 9). Two were poorly differentiated oncocytic thyroid carcinomas, and two were poorly differentiated follicular thyroid carcinomas. A well-differentiated component was not identified in 2 PDTCs. The DHGTCs were subclassified as follicular thyroid carcinoma (n = 4), classic subtype papillary thyroid carcinoma (n = 4), and oncocytic thyroid carcinoma (n = 1). Molecular evaluation revealed one differentiated high-grade follicular thyroid carcinoma, two poorly differentiated follicular thyroid carcinomas, and two PDTCs with DICER1 gene alterations. A DICER1-altered PDTC, DICER1-altered poorly differentiated follicular thyroid carcinoma, and a poorly differentiated oncocytic thyroid carcinoma had TP53 gene alterations. BRAF V600E immunohistochemistry (IHC) was positive in two cases. PanTRK IHC was positive in two cases, one of which had a confirmed SQSTM1::NTRK3 gene fusion. Immunohistochemistry for PTEN showed loss of expression in two tumors, one of which had a loss of function PTEN germline alteration. Clinical follow-up was available for 14 patients (range 24-347 months, median 101 months). Four patients had local/regional recurrences, and one patient had distant recurrences (bones and liver). At last, follow-up 10 patients were alive with no evidence of disease, 1 was alive with disease, 1 was alive with an unknown status, 1 died of disease, and 1 died of unknown causes. In summary, we report 15 additional cases of pediatric and young adult high-grade follicular cell-derived non-anaplastic thyroid carcinoma, with a subset harboring DICER1 (n = 5), NTRK (n = 2), and PTEN (n = 2) gene alterations. In this limited case series, two patients were dead at the last follow-up. Whether these findings are consistent within this patient population remains to be addressed as more patient series are published.
Indexed as
Identifiers
39636536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.